Just under half of patients receiving an abnormal blood test have follow-up colonoscopy in the short term<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Aug. 5, 2025 (HealthDay News) — Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within six months, according to a study published online July 29 in Gastroenterology<\/em>.<\/p>\n Timothy A. Zaki, M.D., from the University of California, Los Angeles (UCLA), and colleagues analyzed closed claims data to determine the FU-CY rate after an abnormal blood-based test result and identified predictors of FU-CY using national data. The analysis included 6,068 individuals who underwent a commercially available, blood-based colorectal cancer screening test (Shield, Guardant Health) with linked administrative data.<\/p>\n The researchers found that 7.4 percent of individuals had an abnormal result. Of the 228 individuals with at least six months of follow-up, 49 percent received an FU-CY within six months (mean time to FU-CY, 66.4 days). At any time, 128 individuals (56 percent) received an FU-CY (mean time to FU-CY, 98.3 days overall). Individuals with Medicare Advantage (adjusted odds ratio [aOR], 0.26) were less likely to undergo FU-CY within six months versus those with private insurance. FU-CY at six months was also associated with having fewer comorbidities (aOR, 0.90). Age, race\/ethnicity, and U.S. census region were not significant predictors of FU-CY within six months.<\/p>\n “Blood-based colorectal cancer screening is promising, but it only works if individuals complete the follow-up colonoscopy,” senior author Folasade May, M.D., Ph.D., also from UCLA, said in a statement. “More efforts are needed to help patients follow through to actually diagnose and treat the disease.”<\/p>\n Several authors disclosed ties to relevant organizations.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n